Clinical Trial Update: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting on the safety and tolerability of GT0918 in patients with metastatic hormone-sensitive and castration-resistant prostate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Hormone-sensitive Prostate Cancer

Drugs mentioned

• GT0918

Snippet

Sponsor: Suzhou Kintor Pharmaceutical Inc, | Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 2 | Status: COMPLETED | Results posted: 2024-01-02